Hartman Institute for Therapeutic Organ Regeneration

Functional heterogeneity of the bone marrow vascular niche.

TitleFunctional heterogeneity of the bone marrow vascular niche.
Publication TypeJournal Article
Year of Publication2009
AuthorsKopp H-G, Hooper AT, Avecilla ST, Rafii S
JournalAnn N Y Acad Sci
Volume1176
Pagination47-54
Date Published2009 Sep
ISSN1749-6632
KeywordsAnimals, Bone Marrow, Endothelium, Vascular, Fluorouracil, Hematopoietic Stem Cells, Mice, Mice, Inbred C57BL, Regeneration, Stem Cell Niche, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor Receptor-3
Abstract

<p>Sinusoidal endothelial cells (SECs) comprise the platform where trafficking into and out of the BM occurs and where hematopoietic stem and progenitor cells (HSPC) harbor and receive cues for self-renewal, survival, and differentiation. Therefore, SECs are referred to as a bone marrow vascular niche (BMVN). Hematopoietic regeneration has been shown to occur only with concurrent angiogenic regeneration. However, there are still not sufficient means to identify and isolate SECs, therefore the "niche endothelial cell" remains incompletely characterized. VEGF-receptor-3 (VEGFR3) is expressed exclusively by the SECs, while Sca1 and Tie2 are only expressed on the VEGFR3(-) arteriolar endothelium. We previously demonstrated the importance of vascular recovery in hematopoietic regeneration from myelosuppression due to cytotoxic agents or whole-body irradiation. Therefore to establish the functional importance of SECs, the mechanisms underlying BMVN regeneration were examined utilizing a 5-fluorouracil (5-FU) myelosuppression model of vascular damage. Injection of antibodies against murine VEGFR-1 and -2 had no significant effect on hemangiogenic recovery. However, when soluble VEGFR-1, a decoy receptor for VEGF-A and PlGF, was injected after 5-FU, both angiogenic remodeling and regeneration of megakaryopoiesis were delayed. In conclusion, we show that the bone marrow vasculature comprises heterogeneous compartments. SECs are distinguished from arterioles by unique immunophenotypes. Regeneration of damaged SECs is the rate-limiting step in hematopoietic regeneration from myelosuppressive therapy. Novel, high-efficiency VEGF-binding drugs in combination with chemotherapeutic agents may lead to cases of prolonged cytopenia.</p>

DOI10.1111/j.1749-6632.2009.04964.x
Alternate JournalAnn N Y Acad Sci
PubMed ID19796232
PubMed Central IDPMC2945889
Grant ListP01 HL059312-090006 / HL / NHLBI NIH HHS / United States
R01 HL061849-04 / HL / NHLBI NIH HHS / United States
P01 HL072942-010004 / HL / NHLBI NIH HHS / United States
R01 HL061849-03S1 / HL / NHLBI NIH HHS / United States
R01 HL061849-05 / HL / NHLBI NIH HHS / United States
U01 HL066952-040002 / HL / NHLBI NIH HHS / United States
P01 HL059312-080006 / HL / NHLBI NIH HHS / United States
R01 HL075234 / HL / NHLBI NIH HHS / United States
R21 HL083222-01 / HL / NHLBI NIH HHS / United States
R01 HL075234-04 / HL / NHLBI NIH HHS / United States
U01 HL066952 / HL / NHLBI NIH HHS / United States
P01 HL067839-020004 / HL / NHLBI NIH HHS / United States
P50 HL084936 / HL / NHLBI NIH HHS / United States
R01 HL058707-04 / HL / NHLBI NIH HHS / United States
P01 HL059312-100006 / HL / NHLBI NIH HHS / United States
P01 HL072942 / HL / NHLBI NIH HHS / United States
U01 HL066952-030002 / HL / NHLBI NIH HHS / United States
P50 HL084936-010003 / HL / NHLBI NIH HHS / United States
R21 HL083222-02 / HL / NHLBI NIH HHS / United States
P50 HL084936-030003 / HL / NHLBI NIH HHS / United States
P01 HL067839 / HL / NHLBI NIH HHS / United States
R01 HL075234-03 / HL / NHLBI NIH HHS / United States
U01 HL066952-020002 / HL / NHLBI NIH HHS / United States
R01 HL058707-03 / HL / NHLBI NIH HHS / United States
P01 HL059312-060006 / HL / NHLBI NIH HHS / United States
P50 HL084936-020003 / HL / NHLBI NIH HHS / United States
P01 HL059312 / HL / NHLBI NIH HHS / United States
R01 HL061849-03 / HL / NHLBI NIH HHS / United States
R01 HL061849 / HL / NHLBI NIH HHS / United States
P01 HL067839-050004 / HL / NHLBI NIH HHS / United States
P01 HL067839-030004 / HL / NHLBI NIH HHS / United States
P01 HL059312-070006 / HL / NHLBI NIH HHS / United States
P50 HL084936-040003 / HL / NHLBI NIH HHS / United States
P01 HL067839-010004 / HL / NHLBI NIH HHS / United States
R01 HL075234-01 / HL / NHLBI NIH HHS / United States
R01 HL061849-02 / HL / NHLBI NIH HHS / United States
U01 HL066952-050002 / HL / NHLBI NIH HHS / United States
U01 HL066952-010002 / HL / NHLBI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
P01 HL067839-040004 / HL / NHLBI NIH HHS / United States
R21 HL083222 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065